Methods for adjusting for bias due to crossover in oncology trials.
AffiliationEvidera, 7575 Trans-Canada Highway, Suite 500, St-Laurent, QC, H4T 1V6, Canada
MetadataShow full item record
AbstractTrials of new oncology treatments often involve a crossover element in their design that allows patients receiving the control treatment to crossover to receive the experimental treatment at disease progression or when sufficient evidence about the efficacy of the new treatment is achieved. Crossover leads to contamination of the initial randomized groups due to a mixing of the effects of the control and experimental treatments in the reference group. This is further complicated by the fact that crossover is often a very selective process whereby patients who switch treatment have a different prognosis than those who do not. Standard statistical techniques, including those that attempt to account for the treatment switch, cannot fully adjust for the bias introduced by crossover. Specialized methods such as rank-preserving structural failure time (RPSFT) models and inverse probability of censoring weighted (IPCW) analyses are designed to deal with selective treatment switching and have been increasingly applied to adjust for crossover. We provide an overview of the crossover problem and highlight circumstances under which it is likely to cause bias. We then describe the RPSFT and IPCW methods and explain how these methods adjust for the bias, highlighting the assumptions invoked in the process. Our aim is to facilitate understanding of these complex methods using a case study to support explanations. We also discuss the implications of crossover adjustment on cost-effectiveness results.
CitationMethods for adjusting for bias due to crossover in oncology trials. 2014, 32 (6):533-46 Pharmacoeconomics
- Analyzing overall survival in randomized controlled trials with crossover and implications for economic evaluation.
- Authors: Jönsson L, Sandin R, Ekman M, Ramsberg J, Charbonneau C, Huang X, Jönsson B, Weinstein MC, Drummond M
- Issue date: 2014 Sep
- Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study.
- Authors: Faivre S, Niccoli P, Castellano D, Valle JW, Hammel P, Raoul JL, Vinik A, Van Cutsem E, Bang YJ, Lee SH, Borbath I, Lombard-Bohas C, Metrakos P, Smith D, Chen JS, Ruszniewski P, Seitz JF, Patyna S, Lu DR, Ishak KJ, Raymond E
- Issue date: 2017 Feb 1
- Sunitinib for the treatment of gastrointestinal stromal tumours: a critique of the submission from Pfizer.
- Authors: Bond M, Hoyle M, Moxham T, Napier M, Anderson R
- Issue date: 2009 Sep
- Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States.
- Authors: Casciano R, Chulikavit M, Perrin A, Liu Z, Wang X, Garrison LP
- Issue date: 2012
- Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring.
- Authors: Latimer NR, Abrams KR, Siebert U
- Issue date: 2019 Mar 29